The veterinary vaccine manufacturers industry in the Nordics is evolving rapidly, catering to emerging health needs in pets and livestock. Companies in this field focus on developing effective vaccines to prevent diseases, enhancing the overall well-being of animals. With a commitment to innovation, the industry witnesses increasing investments in research and development, collaborating with biotech firms to advance new technologies. Recent trends show a rising interest in personalized medicine and biopharmaceuticals, which address specific health challenges. As veterinarians prioritize preventive care, the sector is poised for growth, reflecting the critical link between animal health and public safety.


The list features 13 prominent investors active in the veterinary vaccine manufacturers sector, showcasing various types such as venture capital and private equity firms. These investors, headquartered primarily in Stockholm and Copenhagen, vary in size from small agile firms to large established ones. Founded between 1963 and 1999, they have collectively engaged in 143 investments in 2024, demonstrating lucrative opportunities in the veterinary space. Their diverse strategies and substantial capital commitments signal a robust interest in supporting innovation in animal healthcare and vaccine development.


Top 13 Veterinary Vaccine Manufacturers Investors in the Nordics


1. Novo Holdings

  • Website: novoholdings.dk
  • Type: Venture Capital
  • Headquarters: Hellerup, Denmark
  • Founded year: 1999
  • Headcount: 51-200
  • Number of deals in 2024: 45
  • LinkedIn: novo-a-s

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages the assets of the Novo Nordisk Foundation and focuses on investing in life science companies at various stages of development. The firm provides capital and strategic support to enhance healthcare solutions. Notably, Novo Holdings has invested in several companies relevant to veterinary medicine, including Invetx, which raised $60.5 million to advance its monoclonal antibody pipeline for treating chronic diseases in dogs and cats. They also have a stake in Minervax, which raised significant funding for its projects, potentially related to vaccine development. These transactions highlight Novo Holdings' commitment to supporting innovations in veterinary health, making them a relevant investor in the veterinary vaccine manufacturers sector.


2. Almi

  • Website: almi.se
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 201-500
  • Number of deals in 2024: 7
  • LinkedIn: almi-ab

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden. Almi aims to enhance the growth and competitiveness of these businesses through tailored financial solutions and guidance. Among its notable transactions, Almi has invested in PreVet, which raised $1,762,180 in a venture round in March 2021, indicating a focus on veterinary applications. Additionally, Almi has participated in funding rounds for other health-related startups, such as Amferia, which develops medical products aimed at combating infections. These investments suggest that while Almi is not exclusively focused on veterinary vaccines, it does engage with companies that operate within the veterinary and health sectors, showcasing its potential relevance in this area.


3. EQT Group

  • Website: eqtgroup.com
  • Type: Private Equity
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 1001-5000
  • Number of deals in 2024: 30
  • LinkedIn: eqt-partners

EQT Group is a prominent investment firm founded in 1994, specializing in private equity, infrastructure, real estate, growth equity, and venture capital. Based in Stockholm, Sweden, EQT serves institutional investors by managing diverse investment portfolios across various sectors and geographies. In the veterinary sector, EQT has made significant investments, including a substantial stake in IVC Evidensia, Europe's largest veterinary care provider, and acquisitions of Evidensia Djursjukvård, Independent Vetcare, and VetPartners. These transactions highlight EQT's commitment to enhancing veterinary services, which are integral to the veterinary vaccine market. Their involvement in these companies positions them as a key player in the veterinary industry, making them a relevant investor in the context of veterinary vaccines.


4. Flerie

  • Website: flerie.com
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 2011
  • Headcount: 1-10
  • Number of deals in 2024: 2
  • LinkedIn: flerie

Flerie is a venture capital firm based in Stockholm, Sweden, founded in 2011. The firm specializes in life sciences, with a strong focus on biotech and pharmaceutical investments. Flerie supports its portfolio of over 30 companies by providing resources and expertise to navigate drug development challenges. They operate primarily in Europe, Israel, and the US, aiming to create long-term value through strategic investments. Notably, Flerie has been involved in several transactions that highlight their interest in vaccine development. For instance, they participated in funding rounds for Prokarium, a biotech company that is developing innovative synthetic biology techniques for creating new vaccines, including those targeting infectious diseases. This involvement in vaccine-related projects positions Flerie as a relevant investor in the veterinary vaccine manufacturers sector, as the technologies developed could have applications in both human and veterinary medicine.


5. Sunstone Life Science Ventures


Sunstone Life Science Ventures is a venture capital firm based in Copenhagen, Denmark, founded in 2007. The firm specializes in investments in early-stage life science companies, focusing on therapeutics, medical technology, and diagnostics. Sunstone provides funding and business development support to help its portfolio companies navigate the path from research to market. Notably, Sunstone has been involved in significant transactions, including a recent investment in Minervax, a Danish biotech company that raised €72M ($76.5M) to advance its GBS vaccine candidate, which has received PRIME status from the European Medicines Agency. This investment highlights Sunstone's engagement in the vaccine development space, which, while primarily focused on human health, indicates a potential interest in vaccine technologies that could also be applicable to veterinary medicine.


6. Industrifonden

  • Website: industrifonden.com
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1979
  • Headcount: 11-50
  • Number of deals in 2024: 9
  • LinkedIn: industrifonden

Industrifonden is a venture capital fund based in Stockholm, Sweden, founded in 1979. The firm specializes in investing in early-stage companies, particularly in the fields of Deep Tech, Life Science, and Transformative Tech. They provide financial support and strategic guidance to startups, helping them scale their innovative solutions. In recent transactions, Industrifonden has invested in Minervax, a Danish biotech company focused on developing a vaccine candidate for Group B Streptococcus, which is significant for newborn health. This investment, along with their participation in other life science ventures, highlights their commitment to advancing healthcare solutions. Additionally, they have engaged in seed funding for companies like Cellevate, which, while not directly related to veterinary vaccines, showcases their active role in the biotech sector. Overall, Industrifonden's focus on life sciences and their involvement in vaccine development positions them as a relevant investor in the broader context of vaccine manufacturing.


7. Vimian Group

  • Website: vimian.com
  • Type: Corporate
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 2021
  • Headcount: 1001-5000
  • LinkedIn: vimian-group

Vimian Group is an animal health company based in Stockholm, Sweden, founded in 2021. The company is dedicated to improving animal health through innovative diagnostics, treatments, and veterinary services, catering to veterinary professionals and pet owners. Vimian operates globally and has made significant strides in the veterinary sector through various acquisitions. Notably, they acquired Bova Holdings Limited, a specialty pharmaceuticals company for companion animals, and Kahu Vet Group, a supplier of veterinary surgical products in New Zealand and Australia. Additionally, Vimian's subsidiary, Nextmune, acquired Laboratoire de Dermo-Cosmétique Animale, enhancing their dermatology product offerings. Their acquisition of IMEX, known for high-quality orthopedic products in the veterinary market, further demonstrates their commitment to expanding their influence in the veterinary health sector. These transactions highlight Vimian's strategic focus on enhancing animal health solutions, which may include veterinary vaccines as part of their broader portfolio.


8. Nordic Capital

  • Website: nordiccapital.com
  • Type: Private Equity
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1989
  • Headcount: 201-500
  • Number of deals in 2024: 10
  • LinkedIn: nordic-capital

Nordic Capital is a private equity firm based in Stockholm, Sweden, founded in 1989. The firm specializes in investments across various sectors, including healthcare and technology, with a strong focus on creating long-term value and sustainability. Nordic Capital partners with management teams to drive growth and operational improvements in its portfolio companies. Notably, they have made significant investments in the veterinary sector, including the acquisition of AniCura, a prominent player in veterinary care, which highlights their commitment to the veterinary industry. Additionally, they have been involved in various healthcare-related transactions, such as their investments in Advanz Pharma, further showcasing their expertise in the healthcare domain. Their diverse investment strategy and focus on sustainable growth make them a relevant player in the veterinary vaccine manufacturers space.


9. Polaris Private Equity


Polaris Private Equity is a private equity firm based in Copenhagen, Denmark, founded in 1998. The firm specializes in investment management, focusing on supporting mid-sized companies in the Nordic region through tailored investment strategies that include private equity, flexible capital, and public equity. Polaris partners with management teams to drive growth and operational improvements, helping these companies realize their full potential. In recent years, Polaris has made significant acquisitions in the veterinary sector, including FaunaPharma and Salfarm in 2024, which are likely involved in veterinary pharmaceuticals or vaccines. These transactions highlight Polaris's commitment to investing in companies that can contribute to the veterinary vaccine market, further solidifying their relevance in this industry.


10. Maki.vc

  • Website: maki.vc
  • Type: Venture Capital
  • Headquarters: Helsinki, Uusimaa, Finland
  • Founded year: 2018
  • Headcount: 1-10
  • Number of deals in 2024: 11
  • LinkedIn: maki-vc

Maki.vc is a venture capital firm based in Helsinki, Uusimaa, Finland, founded in 2018. The firm specializes in seed-stage investments in deep tech and brand-driven companies, providing funding and support to early-stage startups to help them navigate growth and innovation challenges. Maki.vc operates primarily in the Nordic region but maintains a global investment mandate. Notably, Maki.vc has participated in funding rounds for companies like Baseimmune, which is developing vaccine candidates for various health threats, including African swine fever, and Alvar Pet, which is likely focused on veterinary applications. Their involvement in these transactions highlights their interest in the biotech sector, particularly in vaccine development, making them a relevant player in the veterinary vaccine manufacturers space.


11. Altor Equity Partners

  • Website: altor.com
  • Type: Private Equity
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 2003
  • Headcount: 51-200
  • Number of deals in 2024: 6
  • LinkedIn: altor

Altor Equity Partners is a private equity investment management firm based in Stockholm, Sweden, founded in 2003. The firm specializes in enhancing operational efficiency and sustainable growth for its partners through tailored investment strategies and digital transformation solutions. Altor has been involved in several significant transactions in the animal health sector, including the acquisition of Hamlet Protein, a Danish producer of high value-add young animal feed, and EWOS, a leading aquaculture feed producer. These investments reflect Altor's focus on the animal health and nutrition industries, which are closely related to veterinary care and vaccines, indicating their potential interest in the veterinary vaccine market.


12. Indutrade Life Science

  • Website: indutrade.se
  • Type: Corporate
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1978
  • Headcount: 1001-5000
  • Number of deals in 2024: 14
  • LinkedIn: indutrade-life-science

Indutrade Life Science is a corporate investor based in Stockholm, Sweden, founded in 1978. The company is part of an industrial group that focuses on developing and acquiring companies with high technical expertise across various sectors, including technology and industrial solutions. Indutrade emphasizes long-term relationships with its customers and operates through a decentralized structure, allowing its subsidiaries to maintain independence while benefiting from the group's resources. In 2024, Indutrade has been active with 14 investments, including the acquisition of ATLINE ApS, which specializes in quality assurance for the pet food and feed industries. This acquisition highlights Indutrade's engagement in the animal health sector, which is relevant to veterinary vaccines. Other acquisitions, such as Krämer AG and Medexa Diagnostisk Service AB, further demonstrate Indutrade's strategy of expanding its portfolio in related fields, although they do not directly pertain to veterinary vaccines.


13. Knutsson Holdings AB

  • Website: knutsson.se
  • Type: Corporate
  • Headquarters: Gothenburg, Västra Götaland, Sweden
  • Founded year: 1963
  • Headcount: 1-10
  • Number of deals in 2024: 2
  • LinkedIn: knutsson-holdings

Knutsson Holdings AB is a family-owned investment holding company based in Gothenburg, Sweden, founded in 1963. The firm invests in a diverse range of industries, including eGaming, healthcare, and real estate, providing capital and strategic guidance to foster growth and innovation. Notably, in December 2010, Knutsson Holdings participated in a venture round for Intervacc, raising approximately $4.38 million. Intervacc is known for its work in the veterinary vaccine sector, which highlights Knutsson Holdings' engagement in this industry, despite their broader investment portfolio.



Veterinary Vaccine Manufacturers Insights: Key Investors in the Nordics


InvestorHeadquarterSizeFoundedDeals 2024
Novo HoldingsHellerup, Denmark51-200199945
AlmiStockholm, Stockholm, Sweden201-50019947
EQT GroupStockholm, Stockholm, Sweden1001-5000199430
FlerieStockholm, Stockholm, Sweden1-1020112
Sunstone Life Science VenturesCopenhagen, Denmark1-1020071
IndustrifondenStockholm, Stockholm, Sweden11-5019799
Vimian GroupStockholm, Stockholm, Sweden1001-500020210
Nordic CapitalStockholm, Stockholm, Sweden201-500198910
Polaris Private EquityCopenhagen, Denmark51-20019984
Maki.vcHelsinki, Uusimaa, Finland1-10201811
Altor Equity PartnersStockholm, Stockholm, Sweden51-20020036
Indutrade Life ScienceStockholm, Stockholm, Sweden1001-5000197814
Knutsson Holdings ABGothenburg, Västra Götaland, Sweden1-1019632


Want to find more investors focusing on the veterinary vaccine manufacturers industry?

If you want to find more investors that are active in the veterinary vaccine manufacturersindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!